Azitra Announces Pricing of $1.5 Million Public Offering of Common Stock

Core Viewpoint - Azitra, Inc. has announced a public offering of 4,857,780 shares of common stock at a price of $0.30 per share, aiming to raise approximately$1.5 million for working capital and corporate purposes [1]. Company Overview - Azitra, Inc. is a clinical-stage biopharmaceutical company focused on precision dermatology, with its lead product ATR-12 targeting Netherton syndrome, a rare skin disease with no approved treatments [5]. - ATR-12 is currently in a Phase 1b clinical trial for adult patients with Netherton syndrome, while ATR-04 is being developed for EGFR inhibitor-associated rash, which affects around 150,000 people in the U.S. [5]. - The company utilizes a proprietary platform of engineered proteins and a microbial library of approximately 1,500 bacterial strains, enhanced by AI and machine learning technologies [5]. Offering Details - The public offering is conducted under an effective shelf registration statement filed with the SEC, and the offering is expected to close on January 16, 2025 [3][1]. - Maxim Group LLC is acting as the sole placement agent for this offering [2].